Stanford launches rescue trial for transplant patients with Treatment-Resistant complications
NCT ID NCT07484113
Summary
This early-stage trial is testing whether adding sarilumab can help control chronic graft-versus-host disease in adults who didn't respond well to their current treatment, belumosudil. The study will enroll 10 participants at Stanford University to first check if the combination is safe and well-tolerated. Researchers will also look for early signs that it might help reduce disease symptoms in these difficult-to-treat patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.